Bio-Medical Applications Of Connecticut Inc is categorized under Kidney Dialysis Centers in Meriden, CT .
Bio-Medical Applications Of Connecticut Inc was established in 0, and today employs 1 to 4, earning Unknown per year. This is a Kidney Dialysis Centers business, which does work in the B2C market, and is classified as a Kidney Dialysis Centers, under code number 621492 by the NAICS.
If you are seeking more information, feel free to contact Allison Jenks at the company’s branch by writing to 377 Research Parkway, Meriden, Connecticut CT 06450 or by phoning (203) 639-2880. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Bio-Medical Applications Of Connecticut Inc |
Contact Person: | Allison Jenks |
Address: | 377 Research Parkway, Meriden, Connecticut 06450 |
Phone Number: | (203) 639-2880 |
Website Address: | ctnurses.org |
Annual Revenue (USD): | Unknown |
Location Type: | Branch |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Kidney Dialysis Centers |
SIC Code: | 8092 |
NAICS Code: | 621492 |
Share This Business: |
Bio-Medical Applications Of Connecticut Inc was started in 0 to provide professional Kidney Dialysis Centers under the SIC code 8092 and NAICS code 621492. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Allison Jenks for inquiries that concern Bio-Medical Applications Of Connecticut Inc by calling the company number (203) 639-2880, as your correspondence is most welcome. Additionally, the physical location of the branch of Bio-Medical Applications Of Connecticut Inc can be found at the coordinates 41.516018,-72.765601 as well as the street address 377 Research Parkway in Meriden, Connecticut 06450.
For its online presence, you may visit Bio-Medical Applications Of Connecticut Inc’s website at ctnurses.org and engage with its social media outlets through on Twitter and on Facebook.